Nephrosant is developing diagnostic tools for early detection of kidney disease. Chronic kidney disease is a global health crisis, affecting 1 in 9 people worldwide, with one treatment option being kidney transplantation. However, about 10% of kidney transplants each year are re-transplants in patients with graft loss. To solve this, Nephrosant has created QSant, a non-invasive, urine-based test that optimizes early detection of kidney rejection risk. The risk score provided by QSant can enable clinicians to provide actionable, personalized care. In addition, Nephrosant is dedicated to understanding the spectrum of kidney disease to support long-term monitoring of kidney health.

<p>Nephrosant is developing diagnostic tools for early detection of kidney disease. Chronic kidney disease is a global health crisis, affecting 1 in 9 people worldwide, with one treatment option being kidney transplantation. However, about 10% of kidney transplants each year are re-transplants in patients with graft loss. To solve this, Nephrosant has created QSant, a non-invasive, urine-based test that optimizes early detection of kidney rejection risk. The risk score provided by QSant can enable clinicians to provide actionable, personalized care. In addition, Nephrosant is dedicated to understanding the spectrum of kidney disease to support long-term monitoring of kidney health.</p>


NephroSant

Founded: 2015
Location: Brisbane, CA
Employee range: 50 - 200
Funding: $16M A Mar 2021

Short description:

Drug notes:

Long description:

Jobs: